Literature DB >> 19775326

Family information service participation increases the rates of mutation testing among members of families with BRCA1/2 mutations.

Henry T Lynch1, Carrie L Snyder, Jane F Lynch, Sumedha Ghate, Steven A Narod, Gordon Gong.   

Abstract

Some members of hereditary breast-ovarian cancer (HBOC) families may not participate in BRCA testing to determine their mutation status in part because they are unaware of their cancer risk and the availability of BRCA testing. Participation in a family information service (FIS), of which we have provided more than 100 sessions during the past 30 years, has been seen to effectively allow family members to be educated regarding their cancer genetic risk and potential benefits from cancer control measures such as mutation testing. However, the effect of the FIS on the rate of mutation testing has not been studied. One thousand five hundred seventy-four eligible (>18-year old, at a 25% or higher pedigree risk) members from 60 extended HBOC families with BRCA1/2 mutations were invited to attend a FIS to learn about their risk and undergo genetic testing. The rates of mutation testing were compared between those who had attended an FIS, and those who had not with chi-squared test and logistic regression analysis. Seventy five percent (334/444) of FIS attendees had undergone mutation testing following or during an FIS which was significantly higher than the 33.8% (382/1130) rate among nonattendees (p < 0.0001). Logistic regression analysis showed that FIS attendance, breast-ovarian cancer history, gender, and age were significant variables for undertaking a mutation test. FIS attendance significantly increased the rate of mutation testing among high-risk family members.

Entities:  

Mesh:

Year:  2009        PMID: 19775326      PMCID: PMC2760017          DOI: 10.1111/j.1524-4741.2009.00807.x

Source DB:  PubMed          Journal:  Breast J        ISSN: 1075-122X            Impact factor:   2.431


  11 in total

1.  Family information service and hereditary cancer.

Authors:  H T Lynch
Journal:  Cancer       Date:  2001-02-15       Impact factor: 6.860

2.  Is GINA worth the wait?

Authors:  Mark A Rothstein
Journal:  J Law Med Ethics       Date:  2008       Impact factor: 1.718

3.  Outcome of surveillance and prophylactic salpingo-oophorectomy in asymptomatic women at high risk for ovarian cancer.

Authors:  Paul A M Meeuwissen; Caroline Seynaeve; Cecile T M Brekelmans; Hanne J Meijers-Heijboer; Jan G M Klijn; Curt W Burger
Journal:  Gynecol Oncol       Date:  2005-05       Impact factor: 5.482

4.  Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers.

Authors:  L C Hartmann; T A Sellers; D J Schaid; T S Frank; C L Soderberg; D L Sitta; M H Frost; C S Grant; J H Donohue; J E Woods; S K McDonnell; C W Vockley; A Deffenbaugh; F J Couch; R B Jenkins
Journal:  J Natl Cancer Inst       Date:  2001-11-07       Impact factor: 13.506

Review 5.  Hereditary breast-ovarian cancer at the bedside: role of the medical oncologist.

Authors:  Henry T Lynch; Carrie L Snyder; Jane F Lynch; Bronson D Riley; Wendy S Rubinstein
Journal:  J Clin Oncol       Date:  2003-02-15       Impact factor: 44.544

6.  Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers.

Authors:  T R Rebbeck; A M Levin; A Eisen; C Snyder; P Watson; L Cannon-Albright; C Isaacs; O Olopade; J E Garber; A K Godwin; M B Daly; S A Narod; S L Neuhausen; H T Lynch; B L Weber
Journal:  J Natl Cancer Inst       Date:  1999-09-01       Impact factor: 13.506

Review 7.  Peritoneal carcinoma in women with genetic susceptibility: implications for Jewish populations.

Authors:  Murray Joseph Casey; Chhanda Bewtra
Journal:  Fam Cancer       Date:  2004       Impact factor: 2.375

8.  Cancer risk assessment: quality and impact of the family history interview.

Authors:  Harvey J Murff; Daniel Byrne; Sapna Syngal
Journal:  Am J Prev Med       Date:  2004-10       Impact factor: 5.043

9.  Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2.

Authors:  Mary-Claire King; Joan H Marks; Jessica B Mandell
Journal:  Science       Date:  2003-10-24       Impact factor: 47.728

10.  Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group.

Authors:  Timothy R Rebbeck; Tara Friebel; Henry T Lynch; Susan L Neuhausen; Laura van 't Veer; Judy E Garber; Gareth R Evans; Steven A Narod; Claudine Isaacs; Ellen Matloff; Mary B Daly; Olufunmilayo I Olopade; Barbara L Weber
Journal:  J Clin Oncol       Date:  2004-02-23       Impact factor: 44.544

View more
  2 in total

Review 1.  Predictors of genetic testing decisions: a systematic review and critique of the literature.

Authors:  Kate Sweeny; Arezou Ghane; Angela M Legg; Ho Phi Huynh; Sara E Andrews
Journal:  J Genet Couns       Date:  2014-04-11       Impact factor: 2.537

2.  Sharing genetic risk with next generation: mutation-positive parents' communication with their offspring in Lynch Syndrome.

Authors:  Katja I Aktan-Collan; Helena A Kääriäinen; Eeva M Kolttola; Kirsi Pylvänäinen; Heikki J Järvinen; Ari H Haukkala; Jukka-Pekka Mecklin
Journal:  Fam Cancer       Date:  2011-03       Impact factor: 2.375

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.